EPISODE · Sep 20, 2023
September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
from AAD's Dialogues in Dermatology
Andrew Blauvelt, MD, FAAD interviewed by Jackie Dosal, MD, FAAD
Embed this episode
Ready to play
September JAAD: Efficacy and safety of switching from dupilumab to upadacitinib versus continuous upadacitinib in moderate-to-severe atopic dermatitis: results from an open-label extension of the phase 3, randomized, controlled trial (Heads Up)
0:00
0:00
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
When was this AAD's Dialogues in Dermatology episode published?
This episode was published on September 20, 2023.
Can I download this AAD's Dialogues in Dermatology episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!